Charles Hugh-Jones
Directeur Général chez Volastra Therapeutics, Inc.
Postes actifs de Charles Hugh-Jones
Sociétés | Poste | Début | Fin |
---|---|---|---|
Volastra Therapeutics, Inc.
Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | Directeur Général | - | - |
Historique de carrière de Charles Hugh-Jones
Anciens postes connus de Charles Hugh-Jones
Sociétés | Poste | Début | Fin |
---|---|---|---|
ALLERGAN PLC | Directeur Technique/Scientifique/R&D | 14/08/2018 | 08/05/2020 |
Statistiques
Internationale
Irlande | 2 |
Etats-Unis | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 1 |
Chief Executive Officer | 1 |
Sectorielle
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
Volastra Therapeutics, Inc.
Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | Health Technology |
- Bourse
- Insiders
- Charles Hugh-Jones
- Expérience